Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Exclusion Criteria

• •Conditions which could alter airway reactivity to methacholine (e.g., pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within six weeks prior to the screening visit.
• •History of seasonal asthma exacerbations, in which case the patient should be studied outside of the relevant allergen season.
• •History of a clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia.
• •History of cystic fibrosis, bronchiectasis or other respiratory diseases other than Asthma
• •Historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases
• •Known intolerance or hypersensitivity or hypersensitivity to any component of the albuterol metered dose inhaler (MDI).